Syndax Pharmaceuticals (NASDAQ: SNDX) revenue
Syndax Pharmaceuticals reported revenue of $172.4m for fiscal 2025, 627.8% more than in fiscal 2024 ($23.7m). Since fiscal 2016 its revenue has grown by 14,027.2%, an average growth of 73.3% a year.
Fiscal 2025 is the highest of the 10 fiscal years on record for Syndax Pharmaceuticals. The biggest drop was in fiscal 2018, −28.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $172.4m | +627.8% | −$273.1m | −158.4% |
| 2024 | $23.7m | — | −$339.7m | −1,434.4% |
| 2023 | $0.0m | — | −$230.0m | — |
| 2022 | $0.0m | −100.0% | −$151.8m | — |
| 2021 | $139.7m | +9,109.6% | $26.2m | 18.8% |
| 2020 | $1.5m | 0.0% | −$71.4m | −4,708.2% |
| 2019 | $1.5m | 0.0% | −$57.5m | −3,792.9% |
| 2018 | $1.5m | −28.0% | −$75.9m | −5,001.7% |
| 2017 | $2.1m | +72.8% | −$62.0m | −2,939.0% |
| 2016 | $1.2m | — | −$43.8m | −3,587.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Syndax Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Syndax Pharmaceuticals ranks 256th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Syndax Pharmaceuticals, 627.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 254th | Stoke Therapeutics | $184.4m | 404.5% |
| 255th | Phathom Pharmaceuticals | $175.1m | 216.9% |
| 256th | Syndax Pharmaceuticals | $172.4m | 627.8% |
| 257th | Regenxbio | $170.4m | 104.5% |
| 258th | Ginkgo Bioworks | $170.2m | −25.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Syndax Pharmaceuticals
- How much revenue did Syndax Pharmaceuticals make in fiscal 2025?
- Syndax Pharmaceuticals reported revenue of $172.4m for fiscal 2025, compared with $23.7m in fiscal 2024.
- How much has the revenue of Syndax Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $1.2m to $172.4m: 14,027.2% more, an average growth of 73.3% a year.
- What was the best year for revenue at Syndax Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $172.4m.
- Where does Syndax Pharmaceuticals rank in its sector by revenue?
- It ranks 256th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Syndax Pharmaceuticals come from?
- From the annual report (Form 10-K) that Syndax Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Syndax Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Syndax Pharmaceuticals: the Syndax Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.